

# Index

## A

Abbreviated New Drug Application (ANDA), 288

Ablation, 70, 77, 167, 238, 279, 322, 329, 330, 430–432, 440, 441, 443, 446, 450, 451

Absorption, 70, 81–84, 121, 146, 173, 175, 207, 208, 210, 211, 222, 232, 233, 237, 265, 304, 363, 365, 366, 382, 417, 432, 436, 439–441, 452

Accelerated approval, 34, 289, 291

Active pharmaceutical ingredient (API), 181, 183, 184, 208, 210, 213, 216, 222, 290

Active targeting, 17, 138, 143, 147, 152, 163, 166, 180, 222, 285, 292, 354, 361, 368, 376, 451

Administration routes, 18, 186, 208, 236

Aerosolize, 255–260, 270

Agents, 14, 34, 94, 133, 163, 207, 232, 259, 301, 345, 398, 429, 462

Aggregation, 71, 83, 176, 308, 309, 327, 413

Airan, R.D., 372

Ale, A., 367

Alliance for Nanotechnology in Cancer, 100, 151

Alyass, A., 308

Analytical considerations, 304

Anatomical targeting, 254, 261

Animal research, 219

Anticancer, 24, 52, 55, 75, 163, 212, 220, 231–233, 242, 278, 279, 320, 324, 327–329, 335, 337, 368, 376, 378, 379, 398, 399, 444, 446

Antunes, F., 217

Apoptosis, 51, 144, 238, 259, 322, 332, 396, 398, 399, 401–403, 406, 407, 410–413, 417, 447

Approving drug products containing nanomaterials, 9

Area under curve (AUC), 75, 76, 113

Artificial Intelligence Drug Carriers

## B

505(b)(1), 287, 288

505(b)(2), 287, 288

Bader, M.J., 381

Barenholz, Y.C., 211

Barr, Y., 94

Bhatia, A., 241

Bioavailability, 20, 21, 59, 72, 76, 173, 208, 210, 215, 219–221, 231, 266, 269, 278, 281, 288, 306, 307, 320, 452

Biochemical markers, 346, 415

Biodistribution, 19, 22, 71, 72, 75, 76, 80, 82, 134, 150, 151, 164, 165, 171, 172, 175, 177, 187, 244, 290, 324, 334, 345, 346, 349, 355, 361–364, 367, 374–377, 398, 403, 431, 436, 448, 451, 464

Biological barriers, 9, 14, 15, 18, 26, 68, 164, 170, 174, 366, 409, 468

Biologic license application (BLA), 287, 288, 291

Biomarker (BM), 16, 34, 110, 134, 188, 302, 356, 405, 464

Biomaterials, 396, 467

Biomedical research, 465

Biophysicochemical properties, 170

- Biosensors, 5, 120–123, 145  
 Bishop, J.M., 94  
 Bisht, S., 220  
 Blankenberg, F.G., 406  
 Blood circulation, 17–19, 22, 72, 111, 140, 165, 175, 176, 216, 231, 346, 463  
 Bomba, H.N., 231, 233, 234, 236, 238, 243  
 Bomy Lee Chung, 168  
 Bourlinos, A.B., 417  
 Boveri, T., 94  
 Bozeman, E.N., 13–27  
 Breakthrough therapy designation, 291
- C**  
 Cabral, H., 174  
 Cancer, 6, 13, 33, 109, 133, 163, 208, 234, 254, 277, 346, 395, 429, 461  
 Cancer detection, 16, 26, 35, 38, 43, 133–152, 398  
 Cancer diagnostics, 9, 33–61, 109, 133, 147, 152  
 The Cancer Genome Atlas (TCGA), 95, 117  
 Cancer genomics, 14, 44, 110, 116, 464  
 Cancer metastase, 40, 78, 401  
 Cancer proteomics, 110, 116  
 Cancer stem cells (CSCs), 15, 24, 114, 179, 181  
 Cancer therapeutics, 13–27, 46, 163, 164, 166, 170, 253, 277, 280–284, 292, 293, 331, 377, 404, 413, 418, 463  
 Cancer therapy, 20, 23, 47, 50, 59, 147, 181, 208, 231–244, 255, 291, 305, 307, 346, 355–359, 361, 363, 367–371, 373–384, 396, 397, 399, 403, 408, 409, 416, 430, 431, 444  
 Cancer treatment approach, 178  
 Cancer treatment monitoring, 395–419  
 Cancer vaccines, 54–56, 95, 330  
 Cardiovascular diseases, 5, 6  
 Cellular modality, 380  
 Center for Drug Evaluation and Research (CDER), 278, 285, 288, 289  
 21<sup>st</sup> Century Cures Act, 95  
 Chemical enhancers, 232, 233  
 Chemical permeation enhancers (CPEs), 209  
 Chemotherapeutic drugs, 23, 68, 77, 170, 207, 208, 210, 214, 332, 361  
 Chemotherapeutics, 20, 24, 48, 50, 53, 75, 178, 181, 208, 210, 212, 220, 221, 255, 259, 260, 262–264, 266–268, 322, 331, 334, 335, 345, 379, 410, 413, 433, 448, 462  
 Chemotherapy, 13–17, 19, 23–25, 33, 34, 46, 48, 49, 53, 54, 58, 77, 80, 94, 98, 103, 172, 173, 178, 181, 182, 186, 211, 214, 221, 222, 237, 260, 267, 325, 356–359, 361–364, 372, 374–376, 379, 401, 405, 406, 409, 412, 429, 430, 433, 444, 445, 451, 452  
 Chen, F., 363, 364  
 Chen, M., 233  
 Chen, M.C., 237  
 Chen, X., 395–419  
 Chimeric antigen receptor-T cell therapy (CAR-T), 56, 58, 149  
 Choi, C.H., 174  
 Chow, E.K., 181  
 Circulating tumor cells (CTCs), 43, 44, 114, 123–125, 467  
 Clearance, 22, 36, 72, 98, 134, 174–177, 182, 188, 244, 254–256, 258, 261, 265–267, 269, 324, 334, 346, 383, 407, 415, 416, 419, 430, 436, 452, 463  
 Clinical, 16, 34, 91, 110, 134, 164, 208, 234, 255, 345, 396, 430, 462  
 Clinical efficacy, 14, 25, 207, 278  
 Clinical imaging, 16, 79, 80, 144, 147, 150  
 Clinical translation, 57, 77, 81, 100, 116, 134, 135, 147, 150, 152, 166, 181, 182, 187, 244, 325, 337, 418, 452, 467  
 Clinical trials, 55–59, 61, 70, 77, 86, 102, 103, 134, 136, 147, 151, 166, 167, 172, 180–182, 185, 189, 212, 214, 218, 223, 235, 236, 244, 255, 258, 263, 264, 269, 270, 282–284, 286, 289, 291, 292, 308, 325, 345, 377, 379, 380, 383, 403, 414, 416, 418, 419, 433, 445, 448–452, 462, 466  
 Collins, F.S., 307  
 Colonic drug delivery, 265  
 Combination therapies, 34, 44, 53, 59, 60, 76, 164, 185, 448  
 Combinatorial, 26, 301, 321, 327, 328  
 Companion diagnostics, 34, 36, 39–43, 45, 46, 68, 136, 148, 149, 165, 462, 467  
 Computed tomography (CT), 16, 79–81, 109, 135, 137, 139–141, 147, 346, 360, 366, 379, 381, 397, 401, 407, 413, 416, 437, 439, 463  
 Contrast agents, 16, 45, 68, 79–82, 134–137, 140, 141, 143, 144, 147, 151, 152, 165, 167, 307, 320, 332, 334, 348, 354, 355, 358, 372–374, 376, 377,

- 398–400, 402, 404, 405, 415, 417,  
431, 432, 437, 439, 442, 444, 446,  
462
- Controlled release, 164, 166, 222, 232, 241,  
436, 444
- Critical quality attributes (CQAs), 289–292,  
310, 312
- Currin, E., 409
- D**
- Databases, 45, 304, 311
- DaunoXome®, 98, 212, 279
- de Gouvêa, H., 94
- Delivery routes, 265, 270
- Dendrimers, 140, 166, 167, 232, 262, 290,  
320, 321, 323, 328, 329, 367, 400
- des Rieux, A., 217
- Detappe, A., 382
- Detection, 5, 13, 35, 110, 133, 238, 309, 346,  
395, 431, 461
- Development, 4, 14, 34, 95, 109, 133, 163,  
208, 232, 255, 278, 347, 354, 361,  
365, 370–371, 373, 374, 382, 383,  
396, 444, 447, 450–453, 462
- Diagnostic, 4, 14, 34, 94, 111, 133, 243, 301,  
345, 396, 451, 452
- Diagnostic imaging, 135, 320, 444, 446, 462
- Dialysis systems, 215, 217, 218
- DNA sequencing, 116, 145
- Doll, R., 94
- Donovan, A.J., 207–224
- Doxil®, 59, 68, 98, 135, 187, 211, 212, 279,  
286, 291, 325, 361, 450–452, 462
- Drug, 3, 15, 34, 68, 95, 110, 134, 163, 231,  
253, 277, 301, 319, 345, 396, 429,  
462
- Drug carriers, 17, 19, 21, 22, 27, 135, 278,  
290, 345
- Drug clearance, 267, 430
- Drug compounding, 24, 210, 211, 217, 218, 331
- Drug conjugates, 59, 279, 291, 361
- Drug delivery, 3, 15, 49, 134, 163, 209, 232,  
255, 306, 346, 396, 444, 446, 447,  
452, 463
- Drug delivery approaches, 49, 59
- Drug delivery barriers
- Drug delivery systems (DDSs), 6, 25, 167,  
209–211, 215, 217, 222, 232, 244,  
311, 345–347, 355, 361, 363, 367,  
373, 377, 465
- Drug development, 61, 285, 288, 302, 311,  
403, 462, 466
- Drug formulation, 207, 208, 210, 222, 254,  
256, 260, 266, 306, 325
- Drug product quality, 303
- Drug products, 221, 277, 278, 280, 281,  
286–292, 301–312, 466
- Drug products containing nanomaterials,  
277–293
- Drug release, 25, 137, 143, 173, 181, 210,  
217–219, 253, 262, 263, 265–268,  
290, 307, 320, 325, 345, 347, 349,  
351–353, 355, 358–359, 368,  
372–376, 396, 398, 430–432, 435,  
436, 439, 443, 452, 464
- Drug resistance, 4, 15, 17, 23, 26, 59, 178,  
320, 335, 429, 433, 463
- Drug safety, 34, 286, 302, 303, 307, 312
- Drug substance, 278, 279, 286–288, 307
- Drug targeting, 50, 361
- Dynamic contrast-enhanced, 328, 400, 402
- E**
- Economic drivers, 302, 304
- Efficacy, 14, 34, 68, 98, 163, 231, 253, 278,  
301, 319, 345, 397, 430, 463
- Efim, S., 94
- Ekimov, A.I., 97
- Eliaz, R.E., 383
- Eljamel, M.S., 381
- Encapsulation, 138, 214, 241, 307, 324, 325,  
328
- Endothelium, 72–75, 177, 214, 327, 354, 400
- Energy transfer, 83, 432, 433, 436
- Enhanced permeability and retention (EPR),  
17, 75, 79, 147, 149, 164, 178, 188,  
212, 253, 269, 324, 327, 328, 330,  
332, 383, 446–448, 451, 462
- Epstein, M.A., 94
- Excipients, 186, 305
- Extra cellular matrix (ECM), 21
- F**
- Faraday, M., 96
- Farahani, K., 345–384
- Farber, S., 94
- Farokhzad, O.M., 209, 221, 222
- Fast track designation, 291
- Feng, B., 368
- Ferumoxylol, 136, 151, 356
- Feynman, R., 97, 429
- Fibroblasts, 14, 20–22, 178
- Flash Nanoprecipitation

- Fluorescence, 71, 81, 83, 84, 119, 121–123, 143, 146, 148, 177, 239, 243, 322, 323, 328, 333, 365–369, 371, 376, 377, 381, 410–412, 416, 417, 431, 434, 437, 439, 441, 463
- Fluorescence reflectance imaging (FRI), 410
- Fluorophore-quenching probes, 412
- Food and Drug Administration (FDA), 9, 26, 36, 68, 98, 114, 135, 165, 211, 234, 267, 277, 302, 354, 413, 448, 452, 462
- G**
- Gao, J., 307
- Gd(III)-doped carbon dots, 417
- Generic drugs, 285, 292, 435
- Gene therapy, 6, 56–58, 166, 239, 329, 331, 333, 367, 368, 370–371, 379, 446
- Genetic sequencing, 44
- Genomes, 14, 36, 46, 84, 85, 95, 116–118, 447
- Gogineni, V., 429–453
- Gold nanoparticles (GNPs), 5, 77, 121–123, 141, 186, 243, 284, 320, 321, 329–331
- Gold nanorods (GNRs), 46, 135, 140, 240, 242, 324, 363, 368
- Goldberg, S.W., 94
- Golla, K., 221
- Graham, E., 94
- Grant, J., 319–337
- Green, J.J., 345
- Gu, Z., 231, 233, 234, 236, 238, 243
- Gupta, P.K., 218
- H**
- Hadjipanayis, C.G., 379
- Hallmarks of cancer, 13, 95, 446
- Hamburg, M.A., 307
- Hanahan, D., 13, 95
- Hanes, J., 215
- Hartshorn, C.M., 91–104
- Health, 4, 5, 14, 17, 34, 46, 61, 68, 79, 92, 98, 110–112, 116, 124–125, 135, 141, 146, 182, 233, 277, 279, 285, 286, 291, 301–303, 306–308, 324, 329, 330, 332, 336, 346, 378, 380, 381, 395, 397, 398, 410, 449, 451, 462, 463, 467, 468
- Hertz, R., 94
- Heyn, C., 401
- Hickey, A.J., 301–312
- Hippocrates, 92
- History, 35, 47, 98, 436
- Ho, D., 319–337
- Hopkins, J., 215
- Hormone receptors, 396, 409, 418
- Hughes, K., 277–293
- Human epidermal growth factor 2 (HER2), 25, 34, 40, 51, 95, 103, 166, 185, 405
- Human health, 92, 303
- Hungerford, D., 94
- Hunter, J., 92
- Hydrogels, 210, 214, 266, 267, 433, 435
- Hydrophilicity, 216, 232
- Hyperthermia, 167, 239, 259, 329, 358–359, 368, 376, 377, 435, 444–446, 449–451
- I**
- Ichakawa, K., 94
- Image-guided, 81, 138, 147, 148, 320, 380, 381, 430, 431, 462
- Image-guided drug delivery (IGDD), 9, 23, 27, 345, 347, 354–361, 363, 365–368, 371–374, 376, 377
- Image-guided surgery (IGS), 27, 138, 145, 147–148, 347, 379–381, 431
- Imaging
- agents, 36, 68, 70, 71, 80, 81, 134, 135, 139, 148, 149, 242, 306, 312, 320, 321, 324, 328, 330, 331, 334, 346, 349, 354, 367, 368, 418, 419, 452, 462
- modalities, 16, 35, 36, 38, 61, 79, 91, 134, 135, 145, 152, 322, 324, 333, 347, 354–361, 363, 365–368, 371–374, 376, 377, 380, 403, 415
- Immune
- cells, 14, 20–22, 26, 51, 53–55, 58, 166, 170, 178, 184, 218, 235, 254
- checkpoint inhibitors, 51, 53, 55
- surveillance, 13, 94, 269
- Immunoassays, 118–123
- Immunoliposomes, 77, 212
- Immunotherapies, 3, 13, 14, 17, 25, 26, 46, 52, 53, 59, 95, 123, 149, 166, 182, 184–186, 236, 267, 330, 409, 429
- In vitro*
- diagnostics, 71, 82–86, 111, 149
- In vitro* intestinal co-culture models, 217
- In vivo*
- imaging, 134, 135, 146, 152, 396, 412, 431
- Infectious diseases, 4–6, 54, 57, 92

- Inhalation, 18, 174, 254, 255  
Inheritance, 94  
Inorganic nanocarriers, 237, 240, 242  
Insensitivity, 23  
Intraoperative optical probes, 413  
Intraperitoneal, 7, 18, 170, 171, 242  
Intravenous, 7, 18, 52, 91, 151, 170, 171, 173, 174, 177, 207, 212, 220, 232, 242, 253, 254, 265, 266, 269, 280, 284, 332, 353, 355, 356, 358–359, 362–364, 367, 371, 374–376, 378, 411, 416, 448  
Intravesicular, 254, 267–270  
Investigational new drugs (IND), 164, 165, 186, 286–288, 466  
Iontophoresis, 233–235, 242  
Iron oxide nanoparticles (IONP), 5, 78, 79, 82, 136, 137, 151, 167, 242, 349, 353, 354, 356–357, 374, 376, 379, 382, 399, 415, 417  
Irradiation, 141
- J**  
505(j), 288  
Jadia, R., 3–10  
Jagtap, J.M., 429–453  
Jayalakshmi, Y., 38  
Joh, D.Y., 381  
Joshi, A., 432, 437, 438, 440–443, 445, 447, 449  
Jung, H.-i., 401  
Jung, H.S., 237  
Jung-Rok Lee, 109–126
- K**  
Kaida, S., 399  
Kaittanis, C., 356  
Kamaly, N., 163–189  
Kaplinsky, J., 165  
Kapoor, M., 277–293  
Kartachova, M., 406  
Kee, T., 321, 335  
Kim, S.H., 367  
Kircher, M.F., 413  
Klein, S., 382  
Kohli, M., 69  
Kroto, H.W., 97  
Kulkarni, A., 410  
Kumar, R., 410  
Kydd, J.L., 3–10, 461–468
- L**  
Labouta, H.I., 242  
Langer, R., 173  
Le, P., 78  
Lee, G.Y., 356–357  
Lee, H., 242  
Lee, S., 412, 415  
Lee, Y., 331, 335  
Leo, E., 218  
Li, W.P., 374  
Li, Z., 377  
Ligands, 4, 17, 22, 25, 27, 50, 52, 53, 70, 123, 138, 143, 165, 175, 176, 180, 181, 188, 237, 240, 242, 259, 260, 290, 320, 322, 324, 328, 329, 334, 346, 355, 361, 373, 376, 382, 397, 408, 448, 462, 463  
Lin, P., 382  
Lipid nanocapsules (LNCs), 349, 351–353, 371  
Lipid nanovesicles, 237–239, 241  
Liposomes, 8, 71, 99, 135, 165, 211, 232, 255, 279, 306, 320, 349, 399, 431  
Liquid biopsy, 43, 44, 467  
Liu, C.H., 133–152  
Liu, G., 395–419  
Liu, Y., 209  
Longitudinal proton relaxation, 399  
Lowery, A., 367  
Lu, P.-L., 362–363  
Luo, S., 410
- M**  
Ma, L., 76  
Machine learning (ML), 44, 45  
Macrophages, 14, 20–22, 26, 55, 73, 74, 137, 146, 174, 176, 177, 254, 256–258, 269, 354, 401, 463  
Magnetic, 4, 36, 68, 109, 121, 135, 259, 322, 346, 397, 430  
Magnetic nanoparticles (MNPs), 71, 121, 123–125, 137, 259  
Magnetic resonance, 5, 83, 135–137, 328, 330, 353, 398, 437  
Magnetic resonance imaging (MRI), 5, 16, 36, 45, 71, 79, 109, 135, 136, 167, 320, 332, 346, 347, 354–359, 397, 434, 463  
Manufacturing, 52, 55, 56, 59, 86, 97, 99, 147, 151, 164, 166, 180, 181, 186, 187, 223, 281, 285, 286, 289, 290, 292, 302–304, 306, 310, 312, 383, 452, 466

- Manufacturing considerations, 304  
 Medik, Y.B., 253–270  
 Mesiwala, A.H., 373  
 Metal, 17, 70, 80–84, 96, 142, 146, 167, 235, 309, 323, 330, 332, 354, 397, 399, 417, 439  
 Miao, T., 395–419  
 Micelle, 71, 78, 138, 144, 166–168, 174, 182, 223, 232, 279, 280, 283, 306, 325, 350, 351, 355, 361–363, 367, 399, 400, 434  
 Microfluidic artificial organs, 218  
 Microneedle (MN), 6, 235, 236, 242, 262  
 Microwave, 430–434, 436, 440–442, 449, 451  
 Min Chiu Li, 94  
 Min, H.S., 374–375  
 Miya, D., 326, 335  
 Moghimi, S.M., 174  
 Molecular cellular, 409  
 Molecular imaging, 36, 139, 346, 347, 354–361, 363, 365–368, 371–374, 376, 377, 396–398, 401, 413, 415, 417, 419  
 Molecular modality, 366  
 Monitoring therapeutic response, 110  
 Monoclonal antibodies (mAbs), 25, 50, 52, 53, 95, 103, 134, 189, 282, 292, 334, 364, 400, 405, 468  
 Mononuclear phagocytic system (MPS), 171, 174–176, 188, 311, 463  
 Moore, G., 97  
 Morgagni, G., 92  
 Morris, S.A., 3–10, 91–104, 461  
 Mouli, S.K., 379  
 Mucopenetration, 214  
 Mukherjee, 403  
 Multi/Multiple-drug resistance (MDR), 23, 24, 49, 181, 327, 333, 334  
 Multidrug resistance, 181  
 Multifunctional, 9, 27, 92, 100, 243, 292, 319–337, 373, 376–383, 396, 399, 406, 434, 461, 466, 468  
 Multifunctional nanoparticle, 5, 321, 322, 324, 325, 327–335, 399, 466  
 Multimodal/multimodality imaging, 134, 143, 145, 147, 320, 371, 377, 396, 414–418, 430  
 Multivariate index, 114  
  
**N**  
 Naeim, M., 323, 335  
 Nanocarriers, 59, 77, 81, 99, 166, 167, 215, 217, 218, 232, 237, 238, 240–242, 292, 320, 346, 353, 358, 361, 363, 374, 376, 399, 400, 431, 463  
 Nanocrystals, 417  
 Nanodevices, 5, 45  
 Nanodiagnostics, 5, 133–152, 320, 463, 467  
 Nanodiamonds (NDs), 71, 166, 320–323, 331–333, 335  
 Nanomaterials, 4, 7–9, 45, 59, 77, 81, 85, 86, 97, 134, 145, 146, 163, 170, 186, 189, 253, 277–293, 302, 335, 377, 397, 399, 400, 410, 413, 430, 432, 433, 436, 439, 441, 442, 451, 452, 467  
 Nanomedicine, 4, 59, 68, 100, 149, 164, 212, 231, 233, 237, 244, 253, 307, 319, 366, 396, 430, 461  
 Nanoparticles (NP), 4, 16, 36, 68, 98, 121, 133, 163, 208, 232, 253, 279, 305, 319, 353, 396, 429, 462  
 Nanoprecipitation, 264  
 Nanoscience  
 Nanospheres, 322, 323, 329, 361  
 Nanostructured lipid carriers (NLC), 7  
 Nanostructures, 110, 146, 331, 430, 431, 433, 436, 439, 442, 443  
 Nanotechnologies, 4  
 Nanotechnology, 45, 67, 91, 110, 145, 163, 210, 277, 301, 319, 377, 396, 429, 464  
 Nanotechnology characterization laboratory (NCL), 100, 151, 303, 452  
 Nanotechnology in cancer therapeutics, 292  
 Nanotoxicology  
 Nanotheranostics, 5, 9, 10, 67–86, 302, 307, 311, 312, 345, 346, 355, 358, 363, 365, 367, 368, 373, 376–379, 383, 395–419, 430–433, 436, 438–442, 444, 446, 453, 461–468  
 National Cancer Act, 95  
 National Cancer Institute (NCI), 61, 95, 100, 151, 358–359, 452  
 Nebulizer, 255, 258, 259  
 Negative predictive value (NPV), 113  
 Neurodegenerative diseases, 5, 327  
 New drug application (NDA), 286–288, 291  
 Next-generation sequencing (NGS), 39, 42, 44, 45, 116–118  
 Ng, T.S., 399  
 Nie, L., 418  
 Nixon, R.M., 95  
 Nowell, P., 94  
 Ntziachristos, V., 412  
 Nuclear imaging, 79, 358, 403–409  
 Nuclear medicine, 139, 358, 407

**O**

Obama, B., 95  
Ocular, 254, 260–263  
Oldinski, R.A., 395–419  
Oltmanns, D., 408  
Oncogene, 57, 95, 116, 330, 332  
Oncology, 27, 34, 35, 43, 53, 59–61, 68, 79, 85, 91, 92, 100, 110, 123, 140, 148, 164, 187, 189, 311, 322, 366, 380, 401, 403, 431, 446, 452, 466  
Ooi, C.C., 109–126  
Opsonins, 175  
Optical imaging, 80–82, 135, 138, 147, 346, 347, 363, 365–371, 374, 376, 380, 397, 400, 406, 409–414, 417  
Oral absorption, 207, 208, 210, 211, 222  
Ostwald Ripening

**P**

Pancreatic cancer, 14, 16, 20, 35, 44, 51, 59, 68, 78, 102, 121, 169, 173, 213, 220, 222, 234, 280, 282, 283, 291, 349, 352, 353, 356–357, 374, 414, 419  
Paoli, E.E., 377  
Papanicolaous, G., 94  
Parchur, A.K., 432, 434, 437, 438, 440–443, 445, 447  
Particle size, 17, 139, 241, 278, 280, 290, 291, 306, 308, 309, 312, 323, 324, 327, 328, 332, 334  
Passive targeting, 279, 346, 376, 383  
Permeability, 17, 21, 72, 74, 98, 136, 140, 180, 208, 215–217, 219, 232, 233, 235, 241, 244, 279, 329, 373, 377, 400, 401, 431, 446, 463  
Personalized medicine, 302, 305, 307, 308, 311, 321, 429, 467  
Pharmaceutical, 75, 76, 102, 148, 149, 163, 169, 181, 186, 187, 189, 207, 210, 212–215, 218, 222, 244, 277–279, 281, 286, 291, 304, 324, 346, 452, 453, 464–468  
Pharmacodynamics, 464  
Pharmacokinetics, 19, 50, 59, 75, 76, 80, 82, 164, 165, 175, 210, 218–220, 223, 237, 244, 267, 281, 289, 324, 345, 346, 382, 383, 398, 403, 406, 407, 415, 416, 418, 429, 444, 451  
Phenotypic Personalized Medicine  
Photoacoustic imaging, 135, 140, 141, 242, 417, 418

Photoacoustics (PA), 81, 141, 232, 237, 417, 418  
Photodynamic therapy (PDT), 77, 146, 263, 353, 365, 367, 377, 396, 401, 410, 431, 433, 439, 464  
Photon emission computed tomography, 397  
Photosensitizers (PSs), 365, 367, 377, 380, 410, 431, 436  
Phototherapy, 237, 410  
Photothermal therapy (PTT), 147, 237, 330, 351, 353, 361, 367–369, 410, 418, 436, 440, 464  
Physicochemical properties, 50, 164, 165, 176, 186, 208, 217, 221, 223, 237, 244, 278, 306–308, 310, 320  
Plasmonic, 82, 418, 434  
Polymer, 6, 22, 50, 70, 98, 135, 164, 208, 232, 257, 279, 306, 320, 346, 397, 435  
Polymeric nanoparticles, 208, 214, 216, 220, 223, 237, 239, 241, 242, 307, 312, 323, 399  
Ponce, A.M., 358–359  
Positive predictive value (PPV), 113  
Positron-emission tomography (PET), 16, 36, 38, 45, 81, 135, 139, 143, 144, 320, 322, 350, 360, 361, 363, 364, 377, 379, 397, 403–409, 413–418, 451, 464  
Prabhakar, U., 34  
Preclinical imaging, 137, 333  
Priority review designation, 291  
Protein corona, 121, 175  
Pulmonary, 7, 254–259, 261, 269, 332

**Q**

Quality, 4, 34, 45, 46, 86, 135, 143, 144, 223, 277, 278, 285, 288, 289, 293, 302–304, 306, 309–312, 319, 332–334, 366, 367, 396, 402, 409  
Quality-by-design (QbD), 310  
Quantum dots (QDs), 6, 71, 81–83, 97, 121, 125, 135, 138, 146–147, 174, 240, 262, 323, 353, 376, 383, 410, 412, 415, 431

**R**

Radiation, 3, 15, 17, 33–35, 46, 48, 52, 58, 94, 97, 111, 141, 146, 232, 277, 303, 347, 358, 365, 381, 382, 396, 401, 404, 416, 430, 431, 436, 438–440, 451, 453

- Radiation therapy, 3, 13, 17, 48, 58, 94, 305, 347, 381, 382, 396, 453
- Radionuclide imaging, 397, 400
- Rai, P., 3–10, 461
- Rapoport, N., 374
- Receiver operating characteristic (ROC), 113–116
- Rectal, 254, 265–267, 451
- Regulatory, 9, 26, 34, 45, 46, 53, 58, 60, 147, 148, 151, 152, 186, 189, 211, 212, 223, 277–293, 301–304, 306, 310, 311, 335, 464, 466, 468
- Release kinetics, 217, 218, 222, 290
- Remotely triggered, 346, 464
- Reticuloendothelial system (RES), 19, 22, 346, 354, 362–363, 448, 463
- Rigual, N.R., 381
- Roche, K.C., 253–270
- Rodgers, Z., 253–270
- Roosevelt, F.D., 95
- Routes of administration, 18, 164, 170, 254, 270, 292
- Rowley, J., 94
- Russell, L.M., 133–152
- S**
- Safety, 34, 48, 60, 71, 75, 77, 109, 135, 143, 147, 150–151, 172, 186, 221, 223, 233, 244, 269, 277, 278, 285–289, 292, 293, 301–304, 306–308, 310–312, 320, 327, 332, 378, 383, 416, 441, 448, 451, 452, 462, 464
- Sanger, F., 116
- Sayes, C.M., 305
- Scattering, 5, 70, 81, 97, 139, 142, 151, 291, 307–309, 329, 363, 365, 432, 436, 439, 440, 452
- Schellenberger, E.A., 417
- Secondary Crystallization
- Semiconductor, 4, 70, 71, 77, 81, 145, 397, 417
- Sensitivity, 5, 16, 22, 36, 44, 45, 68, 70, 79–82, 110–114, 121, 139, 142, 143, 145, 152, 207, 214, 291, 322, 324, 346, 347, 356–357, 361, 367, 398, 400–403, 410, 414, 415, 442, 446, 452
- Sharma, G., 429–453
- Silva, L.P., 241
- Single cell analysis, 125
- Sipkins, D.A., 400
- Skin barrier, 232, 233, 237, 238, 241, 244
- Smart medicine, 212
- Smith, A.M., 69
- Soininen, S.K., 383
- Solid Lipid Nanocapsules
- Son, D., 243
- Sonophoresis, 235
- Specificity, 16, 17, 36, 44, 52, 75, 79, 81, 83, 85, 86, 110–114, 145, 152, 182, 259, 320, 329, 334, 379, 383, 401, 406, 440, 465
- Stability, 36, 45, 70, 98, 135, 139, 141, 143, 146, 165, 210, 222, 242, 244, 258, 262, 265, 267, 279, 289, 290, 307, 309, 324, 354, 358, 360, 372, 444, 465
- Stealth liposome, 167, 224
- Stehelin, D., 94
- Stem cell transplantation, 58
- Stylianopoulos, T., 178
- Sumer, B., 307
- Sun, W., 231, 233, 234, 236, 238, 243
- Sun, Y., 409
- Superparamagnetic iron oxide nanoparticles (SPIONs), 82, 143, 259, 399
- Surface design, 214, 215
- Surface-enhanced raman spectroscopy, 135, 142, 145
- Surface modification, 7, 138, 237, 259, 312, 324, 332, 333, 462
- Systematic Clearance
- T**
- Tandon, P. 133–152
- Taniguchi, N., 429
- Targeted, 3, 13, 33, 102, 103, 118, 134, 165, 220, 232, 254, 277, 301, 319, 355, 396, 430, 461
- Targeted nanomedicine, 4, 188, 189
- Targeted therapies, 14, 26, 27, 33, 34, 44, 46, 50–52, 75, 307, 327, 430
- Targeting, 4, 17, 49, 68, 99, 135, 237, 279, 306, 320, 346, 397, 431, 462
- Theranostics, 9, 36, 70, 85, 91, 98–103, 134, 135, 143, 145, 146, 164, 242, 301, 307, 311, 320, 333, 334, 374, 396, 418, 446, 448–451, 462, 465, 468
- Theranostics nanomedicine, 378, 383
- Therapeutic, 3, 14, 34, 68, 94, 110, 125, 134, 163, 210, 231, 253, 277, 320, 345, 395, 429, 462
- Therapeutic efficacy, 34, 68, 136, 147, 176, 179, 244, 254, 258, 259, 263, 270,



- 307, 320, 324, 327, 355–357,  
370–371, 381, 399, 403, 410, 418,  
444, 448, 452, 453, 464
- Therapeutics, 301
- Therapy, 5, 13, 33, 70, 94, 115, 137, 164, 207,  
231, 255, 279, 301, 320, 345, 429,  
461
- Threshold, 60, 72, 75, 111, 113, 114, 177, 212,  
334, 441
- Topical, 231–244, 261, 262, 264
- Toyoda, M., 241
- Transdermal, 233, 234, 236, 238, 239, 243
- Translation, 57, 61, 76, 77, 81, 86, 99–101,  
103, 116, 133–152, 165, 166, 181,  
182, 186, 187, 211, 223, 234–236,  
244, 304, 325, 334, 337, 347, 431,  
452, 453, 464, 465, 467
- Transmucosal permeability, 208, 216, 217, 221
- Transport, 21, 23, 72–76, 172, 177, 179, 187,  
208–210, 215, 217, 218, 221, 231,  
233, 235, 238, 305, 325, 334, 383,  
430, 436
- Transversal proton relaxation, 398, 399
- Treatment efficacy, 68, 208, 231, 260, 265,  
325, 329, 349, 351–353, 356, 367,  
368, 370–371, 374, 398, 409, 418
- Tumor angiogenesis imaging, 399–400
- Tumor biomarkers, 134
- Tumor heterogeneity, 146, 165, 188, 429, 448,  
464
- Tumor imaging, 45, 146, 414, 446
- Tumor microenvironment, 15, 20–22, 25–27,  
50, 51, 53, 109, 136, 144, 146, 170,  
177, 324, 398, 400, 413, 447, 463
- Tumor stroma, 14, 16, 20, 22, 23
- Tumor suppressor, 95, 264, 282
- Tumor vasculature, 15, 17, 21, 178, 253, 269,  
400, 418, 431, 463
- Tumors, 13, 34, 68, 92, 109, 134, 163, 178,  
234, 253, 279, 307, 320, 346, 396,  
429, 462
- Two-phase sink condition, 218
- Tyner, K.M., 277–293
- U**
- Ultrasonography, 346, 372
- Ultrasound (US), 36, 45, 79, 80, 135, 140,  
141, 235, 267, 279, 346, 353,  
371–376, 430–433, 435, 446, 447,  
449, 451, 452, 464
- Ultrasound imaging, 80, 135, 140, 372
- United States Food and Drug Administration  
(USFDA), 78, 277, 303
- United States Pharmacopeia (USP), 302, 303,  
306, 307, 312
- Upconversion nanoparticles (UCNPs), 125,  
141, 146, 410
- Uptake, 20, 22, 23, 25, 74, 76, 79, 139, 165,  
166, 175, 176, 179–181, 187, 188,  
235, 239, 241, 242, 257, 263, 265,  
266, 268, 279, 307, 311, 322, 363,  
378, 379, 383, 408, 416, 431, 437,  
441, 444, 446, 448, 463
- V**
- Vaccine, 46, 53–56, 95, 166, 184, 212, 234,  
236, 277, 283, 306, 330, 468
- Vaginal, 94, 254, 263, 265, 269
- Varmus, H., 94
- Velpurisiva, P., 3–10, 461–468
- Virchow, R., 94
- Vogt, P., 94
- Vong, L.B., 221
- Vu-Quang, H., 376
- W**
- Walsh, L., 236
- Wang, A.Z., 253–270
- Wang, C.K., 47
- Wang, D., 417
- Wang, J., 231, 233, 234, 236, 238, 243, 412
- Wang, L., 368, 370–371, 373
- Wang, S.X., 109–126
- Warner, S., 253–270
- Weinberg, R.A., 13, 95
- Weissleder, R., 134
- White, S.B., 429–453
- Wu, W., 361
- Wu, X., 368
- Wynder, E., 94
- X**
- Xiao, Y., 363
- X-ray, 5, 36, 48, 79–81, 109, 139, 140, 143,  
151, 323, 360, 397, 431–439
- Y**
- Yaghoubi, S.S., 405
- Yamagiwa, K., 94

Yang, L., 13–27  
Ye, Y., 231, 233, 234, 236, 238, 243  
Yong, Y., 147  
You, J., 361  
Youden's index, 113  
Yu, M.K., 356  
Yuan, Y., 413

**Z**

Zamboni, C.G., 378  
Zaric, M., 242  
Zeta potential, 7, 151, 184, 237, 239, 259, 263,  
265, 266, 268, 290, 308, 309, 434  
Zhang, R., 361  
Zhao, P., 368, 369  
Zheng, K., 406  
Zhou, H., 376, 379